Ultrasound-guided Tissue Acquisition of Hepatic Draining Lymph Nodes in the Evaluation of Unresectable Perihilar Cholangiocarcinoma

Overview

About this study

The purpose of this study is to test the feasibility of NanoString digital spatial profiling (DSP) and RNAscope™ on prospectively acquired HDLN tissue samples with EUS-FNB in patients with unresectable perihilar CCA undergoing liver transplant (LT) evaluation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Patients aged 18 years or older referred for liver transplant evaluation at Mayo Clinic Florida for unresectable perihilar CCA without gross evidence of metastatic disease, as evidence by cross-sectional imaging studies.

Exclusion Criteria: 

  • Patients aged 18 years or older referred for liver transplant evaluation at Mayo Clinic Florida for unresectable perihilar CCA found to have evidence of metastatic disease on cross-sectional imaging studies.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 08/20/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Victoria Gomez, M.D.

Contact us for the latest status

Contact information:

Victoria Gomez M.D.

(904) 953-6970

Gomez.Victoria@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20577456

Mayo Clinic Footer